!ID 0000001
!v001!209252
!v002!97
!ID 0000002
!v001!209276
!v002!121
!ID 0000003
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!5
!v701!1
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p align="right"><b><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="2">ARTIGOS    ORIGINAIS</font></b></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000004
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!6
!v701!2
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p>&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000005
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!7
!v701!3
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="4"><b><a name="top10"></a>Immunogenicity    of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial</b>    </font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000006
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!8
!v701!4
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p>&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000007
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!9
!v701!5
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><b><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="3">Imunogenicidade    das vacinas contra febre amarela WHO-17D e 17DD: ensaio randomizado</font></b></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000008
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!10
!v701!6
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p>&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000009
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!11
!v701!7
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p>&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000010
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!12
!v701!8
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Luiz Antonio    Bastos Camacho<sup>I</sup>; Marcos da Silva Freire<sup>II</sup>; Maria da Luz    Fernandes Leal<sup>II</sup>; Savitri Gomes de Aguiar<sup>II</sup>; Jussara Pereira    do Nascimento<sup>II</sup>; Takumi Iguchi<sup>I</sup>; Jos&eacute; de Azevedo    Lozana<sup>I</sup>; Roberto Henrique Guedes Farias<sup>III</sup>; Collaborative    Group for the Study of Yellow Fever Vaccines<a href="#back1"><sup>*</sup></a></b></font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000011
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!13
!v701!9
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><sup>I</sup>Escola    Nacional de Sa&uacute;de P&uacute;blica. Funda&ccedil;&atilde;o Oswaldo Cruz    (Fiocruz). Rio de Janeiro, RJ, Brasil    ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000012
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!14
!v701!10
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<br>   <sup>II</sup>Instituto de Tecnologia em Imunogiol&oacute;gicos. Bio-Manguinhos.    Fiocruz. Rio de Janeiro, RJ, Brasil    ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000013
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!15
!v701!11
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<br>   <sup>III</sup>Instituto de Biologia do Ex&eacute;rcito. Rio de Janeiro, RJ,    Brasil</font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000014
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!16
!v701!12
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><a href="#back10">Correspondence</a></font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000015
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!17
!v701!13
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p>&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000016
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!18
!v701!14
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p>&nbsp;</p> <hr size="1">     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000017
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!19
!v701!15
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>ABSTRACT</b></font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000018
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!20
!v701!16
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>OBJECTIVE: </b>To    compare the immunogenicity of three yellow fever vaccines from WHO-17D and Brazilian    17DD substrains (different seed-lots).    ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000019
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!21
!v701!17
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<br>   </font><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>METHODS:    </b>An equivalence trial was carried out involving 1,087 adults in Rio de Janeiro.    Vaccines produced by Bio-Manguinhos, Fiocruz (Rio de Janeiro, Brazil) were administered    following standardized procedures adapted to allow blocked randomized allocation    of participants to coded vaccine types (double-blind). Neutralizing yellow fever    antibody titters were compared in pre- and post-immunization serum samples.    Equivalence was defined as a difference of no more than five percentage points    in seroconversion rates, and ratio between Geometric Mean Titters (GMT) higher    than 0.67.    ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000020
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!22
!v701!18
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<br>   </font><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESULTS:    </b>Seroconversion rates were 98% or higher among subjects previously seronegative,    and 90% or more of the total cohort of vaccinees, including those previously    seropositive. Differences in seroconversion ranged from -0.05% to -3.02%. The    intensity of the immune response was also very similar across vaccines: 14.5    to 18.6 IU/mL. GMT ratios ranged from 0.78 to 0.93. Taking the placebo group    into account, the vaccines explained 93% of seroconversion. Viremia was detected    in 2.7% of vaccinated subjects from Day 3 to Day 7.    ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000021
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!23
!v701!19
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<br>   </font><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>CONCLUSIONS:    </b>The equivalent immunogenicity of yellow fever vaccines from the 17D and    17DD substrains was demonstrated for the first time in placebo-controlled double-blind    randomized trial. The study completed the clinical validation process of a new    vaccine seed-lot, provided evidence for use of alternative attenuated virus    substrains in vaccine production for a major manufacturer, and for the utilization    of the 17DD vaccine in other countries.</font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000022
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!24
!v701!20
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Keywords: </b>Yellow    fever vaccine. Randomized controlled trials.</font></p> <hr size="1">     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000023
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!25
!v701!21
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000024
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!26
!v701!22
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>OBJETIVO: </b>Comparar    a imunogenicidade de tr&ecirc;s vacinas contra febre amarela ) das subcepas    WHO-17D e 17DD brasileira (diferentes lotes-semente).    ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000025
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!27
!v701!23
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<br>   </font><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>M&Eacute;TODOS:    </b>Trata-se de ensaio de equival&ecirc;ncia envolvendo 1.087 adultos no Rio    de Janeiro, RJ. As vacinas foram produzidas em Bio-Manguinhos, Fiocruz (Rio    de Janeiro, Brasil) e foram administradas seguindo procedimentos adaptados para    randomiza&ccedil;&atilde;o em blocos, com tipos de vacinas codificados ("duplo-cego").    Anticorpos neutralizantes contra febre amarela foram dosados antes e depois    da vacina&ccedil;&atilde;o. Definiu-se equival&ecirc;ncia como diferen&ccedil;a    nas taxas de soroconvers&atilde;o n&atilde;o superior a cinco pontos percentuais,    e raz&atilde;o de t&iacute;tulos m&eacute;dios geom&eacute;tricos superior (TMG)    a 0,67.    ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000026
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!28
!v701!24
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<br>   </font><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESULTADOS:    </b>As taxas de soroconvers&atilde;o foram iguais ou maiores do que 98% nos    participantes previamente soronegativos. Na coorte completa (incluindo os previamente    soropositivos) a soroconvers&atilde;o foi igual ou superior a 90%. As diferen&ccedil;as    na soroconvers&atilde;o variaram de -0,05% a -3,02% entre os grupos de compara&ccedil;&atilde;o.    A intensidade da resposta imune tamb&eacute;m foi semelhante nos grupos: 14,5    UI/mL a 18,6 UI/mL. As raz&otilde;es de TMG variaram de 0,78 a 0,93. Considerando    o grupo placebo, as vacinas explicaram 93% da soroconvers&atilde;o. Viremia    foi detectada entre os dias tr&ecirc;s e sete em 2,7% dos participantes vacinados.    ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000027
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!29
!v701!25
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<br>   </font><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>CONCLUS&Otilde;ES:    </b>A equival&ecirc;ncia na imunogenicidade das vacinas contra a febre amarela    das subcepas 17D e 17DD foi demonstrada pela primeira vez em ensaio cl&iacute;nico    randomizado, duplo-cego, controlado com placebo. O estudo completou o processo    de valida&ccedil;&atilde;o cl&iacute;nica do novo lote-semente de vacina, al&eacute;m    de ampliar as bases para utiliza&ccedil;&atilde;o da vacina brasileira em outros    pa&iacute;ses e de trazer alternativas de subcepas para o produtor da vacina    no Brasil.</font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000028
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!30
!v701!26
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Descritores: </b>Vacina contra febre amarela. Ensaios controlados aleat&oacute;rios.</font></p> <hr size="1">     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000029
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!31
!v701!27
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p>&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000030
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!32
!v701!28
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p>&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000031
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!33
!v701!29
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="3"><b>INTRODUCTION</b></font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000032
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!34
!v701!30
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Yellow fever (YF)    is an acute viral disease of public health importance in Africa and South America,    and of interest for travel clinics in other areas of the world. There is concern    about the potential for urban outbreaks of YF in Latin America with the increase    in the distribution of the <i>Aedes aegypti</i>, increased intrusion of people    into forested areas, and low vaccine coverage.<sup>23,25</sup> In Brazil the    number of reported YF cases has been increasing in the last ten years peaking    in 2000 (85 cases), and approaching more densely populated areas in the Southeast.</font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000033
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!35
!v701!31
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">YF vaccines have    been available since the1930's and constitute the most important method to control    the disease. YF vaccines recommended by the World Health Organization (WHO)    are from 17D and 17DD substrains, which have minor differences in nucleotide    sequences.<sup>6</sup> Control of viral substrains and serial passage levels    through the <i>seed lot system</i> were implemented in the 1940's to avert unwanted    alterations in biological properties of the vaccine.<sup>4</sup> YF vaccines    are now considered safe and highly immunogenic.<sup>16,25</sup> Protective antibodies    induced by the vaccine are experimentally correlated to infection resistance,    and have long duration, possibly life long.<sup>8,18</sup></font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000034
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!36
!v701!32
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Bio-Manguinhos-Funda&ccedil;&atilde;o    Oswaldo Cruz, which is a WHO-prequalified manufacturer linked to the Brazilian    Ministry of Health supplies YF vaccine for Brazil and other countries in South    America and Africa. From 2000 to 2004, 26,368,050 doses of YF vaccine have been    exported to 50 different countries in South and Central America, Africa and    Asia.&nbsp;In Brazil 77,374,755 doses were administered from 1994 to 2002. As    the working <i>seed lot</i> was used up a new seed lot was prepared and tested,    confirming the genetic stability of the virus, its safety in the monkey neurovirulence    test (unpublished data), and freedom from avian leucosis infectious virus.<sup>11</sup>    As part of the process of clinical validation of the new seed lot, it was compared    the immunogenicity and reactogenicity of a vaccine produced from this new seed    lot to that of the already licensed vaccine, to the vaccine produced from WHO    17D-203/77 substrain seed lot, and to placebo. This paper reports the results    of immunogenicity component of the trial. Data on reactogenicity will be the    subject of another publication.</font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000035
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!37
!v701!33
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p>&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000036
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!38
!v701!34
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="3"><b>METHODS</b></font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000037
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!39
!v701!35
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">A randomized field    trial was carried out to test the equivalence of three vaccines in their seroconversion    rates for YF and geometric mean antibody titters (GMT), and to measure the rates    of adverse events, abnormalities in liver enzymes and levels of viremia up to    30 days after immunization. The intent was to demonstrate that the vaccine from    the new seed-lot of the 17DD substrain was at least as immunogenic as the vaccine    from the working seed-lot of the 17DD substrain and a vaccine from the WHO-17D    seed-lot. Vaccine and placebo vials were labeled with codes concealed from the    participants and the field work team. Participants in the placebo group were    vaccinated against YF after the scheduled opening of the codes. The research    protocol was approved by Research Ethics Committees from Funda&ccedil;&atilde;o    Oswaldo Cruz and from the Brazilian Army. Placebo was scientifically justified    for a precise assessment of the reactogenicity and immunogenicity of the vaccines.    It was ethically acceptable since the study area has been free of YF, and immunization    was not routinely conducted there. Two independent reviewers examined the study    protocol and the preliminary results and reported to the steering committee.</font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000038
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!40
!v701!36
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Eligibility assessment,    recruitment of participants, administration of vaccines and blood collection    were carried out in 21 units of the Army located in Rio de Janeiro, Brazil.    Eligibility criteria were age 18 years or more, no previous vaccination against    YF, no plans to travel to YF endemic areas during the study period, availability    for study follow-up, and signed an informed consent. Vaccination history had    to be relied on information from participants. The following conditions constituted    exclusion criteria: (1) pregnancy; (2) immunosuppression due to diseases or    immunosuppressive therapy; (3) history of hypersensitivity to chicken eggs;    (4) administration of any vaccine 30 days before this vaccination; and (5) other    severe disease or fever of 38&ordm;C or higher.</font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000039
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!41
!v701!37
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Trained nurses    adjusted routine immunization procedures to meet the requirements for blinding    and randomization. Participants received a single 0.5 ml subcutaneous injection    in the deltoid region of one of four products: (<i>i</i> ) 17DD vaccine (lot    993PFBEXP03; passage 287) produced from new seed-lot; (<i>ii</i>) 17DD vaccine    (lot 999FB060Z; passage 286; licensed and available at the time of the trial);    (<i>iii</i>) 17D vaccine (lot # 007FBEX01; passage 239) produced from a secondary    seed-lot WHO 213/77/Br 1B/86; and (<i>iv</i>) placebo made of chicken embryo    juice material without YF virus. All vaccines were produced by the Institute    of Immunobiological Technology in Funda&ccedil;&atilde;o Oswaldo Cruz, Rio de    Janeiro. Vaccines were lyophilized, thermostable, and contained <u>&gt;</u>1,000    MLD<sub>50</sub> in each 0.5-ml dose. Vaccines and placebo contained sodium    glutamate, sucrose and &lt;5.0 mg of ovalbumin per dose. Distribution, handling    and administration of the vaccine followed recommendations from the manufacturer    and the Brazilian Program of Immunization.<sup>14</sup> Briefly, freeze-dried    vaccines (or placebo) in 50-doses vials were diluted in sterile and apyrogenic    saline solution, kept between 2&ordm;C and 8&ordm;C, protected from light, and    discarded after four hours.</font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000040
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!42
!v701!38
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Vaccine and placebo    vials looked identical and were labeled with codes, which were concealed from    study participants, field work team, laboratory staff, and data analysts. The    computer-generated randomization scheme (block length =12; uniform allocation    ratio) was also concealed in opaque envelopes, which were opened in predetermined    sequence at the time of vaccine administration.</font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000041
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!43
!v701!39
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Seroconversion    was defined as doubling of pre-vaccination antibody titters and as seropositivity    among individuals with seronegative results in the pre-vaccination test. The    antibody titter was measured with the Plaque Reduction Neutralization Test (PRNT).<sup>5,17</sup>    Serologic analyses were conducted at the Laboratory of Viral Technology at Funda&ccedil;&atilde;o    Oswaldo Cruz.</font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000042
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!44
!v701!40
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Venous blood samples    were drawn just before, between Days 4 and 20, and 30 days or more after vaccination.    Serum aliquots were coded to conceal the identity of the participant and the    timing of collection (pre/post-vaccination). PRNT was conducted in serial two-fold    dilutions starting at 1:5, in 50 &#181;l of inactivated serum in 96 well tissue    culture plates. Thirty plaque forming units (pfu) of 17D strain of YF virus    in 50 &#181;l were dispensed into all wells. Dilutions of virus and serum were    performed in 199 medium containing 2.5% 1M HEPES. A positive monkey serum sample    with YF antibody content calibrated by a WHO International Reference Preparation    was included in each set of test. After incubation at room temperature for 1    hour, 50 &#181;l of a suspension of Vero cells in 199 medium in a density of    1.6x10<sup>5</sup> cells/well was added to all wells and the plates incubated    at 37&ordm;C in 5% CO<sub>2</sub> atmosphere for 3 hours. The medium was discarded    and replaced with 199 medium containing 3.5% carboxymethyl cellulose in volumes    of 100 &#181;l. After incubation at 37&ordm;C in 5% CO<sub>2</sub> atmosphere    for seven days, the monolayers were fixed with formalin, stained with crystal    violet and plaques counted at a magnification of x 12.5 on a vertically mounted    35 mm projector with wide angle lens. The log<sub>10</sub> dilution of the test    and standard serum, which reduced the plaque numbers by 50% relative to the    virus control was determined by linear regression. The mean antibody titter    at the 50% endpoint of the standard serum was then calculated and added to the    log<sub>10</sub> endpoint for each sample to give log<sub>10</sub> mIU/ml. Seropositivity    was defined as YF virus neutralizing antibody titter equal to or higher than    630 mIU/ml (2.8 log<sub>10</sub>). The inter-rater agreement of antibody titters    was assessed through independent tests performed in duplicate serum aliquots    in a 20% sub-sample of participants.</font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000043
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!45
!v701!41
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Signs and symptoms    experienced after immunization were ascertained in an interview and in diary    forms filled in by participants. Serum levels of liver enzymes aspartate aminotransferase    (AST), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (GGT) and    alkaline phosphatase (AP) were measured in all serum samples. Levels of viraemia    were measured in the second (intermediate) blood sample collected between Days    4 and 20 using methods described elsewhere.<sup>9</sup></font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000044
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!46
!v701!42
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">For a one-sided,    non-inferiority equivalence trial it was appropriate to calculate the differences    in seroconversion rates among the vaccine groups, and the ratios of GMT, with    appropriate 90% confidence interval (90% CI) set by the conventional value of    0.05 for a-error.<sup>3</sup> The vaccines were considered similar if the lower    limit of the difference did not exceed -5% and the lower limit of the ratio    of GMT were not less than 0.67.</font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000045
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!47
!v701!43
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">From the comparisons    between each vaccine and the placebo it was derived proportions of seroconversion    attributable to the vaccine, with 95% CI.<sup>2</sup> Antibody titters from    vaccines and placebo were compared in reverse cumulative distribution plots.<sup>19</sup>    Agreement between titters in the subset of sera with two aliquots was measured    with the intraclass correlation coefficient.<sup>1</sup> Analyses were conducted    both for the complete study cohort (intention-to-treat analysis) and for those    who met all protocol requirements.</font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000046
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!48
!v701!44
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Sample size was    based on a null hypothesis of non-equivalence and alternative hypothesis of    equivalence. For beta =0.20, alpha =0.05, a difference no higher than 5 percentage    points, 95% seroconversion rate and 10% attrition rate, the required number    in each group was 240.<sup>1</sup> Epi Info 6.04c and SPSS 10, 1999 were used    for data entry and statistical analysis.</font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000047
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!49
!v701!45
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p>&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000048
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!50
!v701!46
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="3"><b>RESULTS</b></font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000049
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!51
!v701!47
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">From January to    May 2001, 1,087 volunteers received vaccine or placebo, donated pre-vaccination    blood sample and were interviewed. Six (0.6%) of them did not return for post-vaccination    blood collection for reasons unrelated to adverse events. Sera of three individuals    were not available for analysis. Three received other vaccines during the follow-up    and one was 15 years old. A large proportion of participants were found to be    seropositive in pre-vaccination tests (<a href="#tab1">Table 1</a>). They had    a balanced distribution across comparison groups, included the same proportion    of males, but were older than those with seronegative pre-vaccination tests    (median age of 33 and 24 years, respectively).</font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000050
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!52
!v701!48
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p align="center"><a name="tab1"></a></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000051
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!53
!v701!49
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p align="center">&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000052
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!54
!v701!50
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p align="center"><img src="/img/revistas/rsp/v38n5/21755t1.gif"></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000053
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!55
!v701!51
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p align="center">&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000054
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!56
!v701!52
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">The age of participants    ranged from 14.8 to 67.7 years, with comparable means and standard deviations    across groups (<a href="#tab1">Table 1</a>). Young males were highly predominant.</font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000055
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!57
!v701!53
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">In general, the    vaccine was well-tolerated and there were no reports of severe adverse events.    A detailed account of the vaccine reactogenicity is reported elsewhere.</font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000056
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!58
!v701!54
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">The proportion    seropositive after vaccination was above 97% in the complete cohort as well    as in the subset seronegative before vaccination. The immunological response    to all three types of vaccine was similar in the whole range of antibody titters    (<a href="#fig1">Figure 1</a>). The mean and the median antibody titters were    similar for the vaccines (<a href="#tab2">Table 2</a>). More than 90% of those    who received one of the vaccines, including the seropositive in the pre-vaccination    test, showed at least a two-fold increase in their antibody levels (<a href="#tab2">Table    2</a>).</font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000057
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!59
!v701!55
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p align="center"><a name="fig1"></a></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000058
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!60
!v701!56
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p align="center">&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000059
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!61
!v701!57
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p align="center"><img src="/img/revistas/rsp/v38n5/21755f1.gif"></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000060
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!62
!v701!58
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p align="center">&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000061
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!63
!v701!59
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p align="center"><a name="tab2"></a></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000062
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!64
!v701!60
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p align="center">&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000063
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!65
!v701!61
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p align="center"><img src="/img/revistas/rsp/v38n5/21755t2.gif"></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000064
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!66
!v701!62
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p align="center">&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000065
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!67
!v701!63
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Excluding participants    with seropositive pre-vaccination tests, seroconversion was above 98% among    vaccinated groups (<a href="/img/revistas/rsp/v38n5/21755t2.gif">Table 2</a>). GMT from the whole    cohort were very close to GMT obtained in per protocol analysis.</font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000066
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!68
!v701!64
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">The intraclass    correlation coefficient (ICC) for antibody titters in two aliquots of the same    sera was 0.79 (95% CI: 0.74-0.83). The distribution of the differences between    titters was symmetrical, with mean 0.12 and median 0 log<sub>10</sub> mIU/ml.    With seroconversion defined as fourfold increase in pre-vaccination titters,    the rates would have been 96.6%, 98.4%, 98.5% and 2.1% for vaccines produced    from 17DD-013Z, 17DD-102/84, 17D-213/77 seed lots and placebo, respectively.</font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000067
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!69
!v701!65
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">The unexpected    substantial proportion of individuals seropositive to YF before intervention    engendered an analysis of this subset that had not been considered in the protocol.    They showed seroconversion rates of 67%, 76%, 77% and 16% in the groups that    received the vaccines produced from 17DD-013Z, 17DD-102/84, 17D-213/77 seed-lots    and the placebo, respectively. The variation in the placebo group suggested    that part of the seroconversion of vaccines was not explained by the vaccine.    Contrasting the pool of vaccines with placebo controls, the proportion of seroconversion    attributable to immunization was 79% among those with pre-vaccination seropositivity.    The post-vaccination GMT was somewhat higher among vaccinated subjects who were    seronegative (16.2 IU/ml; 95% CI: 14.7-17.8 IU/ml) before vaccination, compared    to those who were seropositive (14.0 IU/ml; 95% CI: 12.0-16.3 IU/ml).</font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000068
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!70
!v701!66
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Analysis of the    complete cohort indicated that 90% of seroconversion among vaccinated subjects    were attributable to the vaccines. Excluding the seropositive before vaccination,    study vaccines explained more than 93% of seroconversion of vaccinated subjects.</font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000069
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!71
!v701!67
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">The differences    between the proportions of post-vaccination seropositivity varied from 0.35%    to -1.95% with lower confidence limits above -5% (data not shown). Differences    in seroconversion ranged from -0.05% to -3.02% (<a href="#fig2">Figure 2</a>).    The lower limit of the 90% confidence interval of the difference between 17DD    vaccines and the 17D vaccine was beyond the limit of equivalence.</font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000070
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!72
!v701!68
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p align="center"><a name="fig2"></a></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000071
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!73
!v701!69
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p align="center">&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000072
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!74
!v701!70
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p align="center"><img src="/img/revistas/rsp/v38n5/21755f2.gif"></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000073
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!75
!v701!71
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p align="center">&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000074
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!76
!v701!72
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">The ratios of post-vaccination    GMT ranged from 0.78 and 0.93, and the 90% CI from vaccines produced from 17DD-013Z    and 17D-213/77 seed lots included the 0.67 limit defined as equivalence (data    not shown).</font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000075
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!77
!v701!73
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Viremia was detected    in only 2.7% of vaccinated subjects (2.2% of those who received 17DD and 3.7%    with 17D), from Day 3 to Day 7 after vaccination.</font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000076
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!78
!v701!74
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Seroconversion    rates for the three vaccine groups pooled together differed slightly across    age-groups: 30 years or more, 95.4%, 25-29 years, 99.5% and 18-24 years, 99.7%.    The GMT for vaccines did not differ substantially across those age groups, though    (17.6, 18.0 and 17.7 IU/ml, respectively). Female volunteers (n=54) showed a    smaller seroconversion rate compared to men: 95.5% and 99.3%, respectively.    Again, the GMT did not differ substantially: 17.9 UI/ml (women) and 17.8 UI/ml    (men).</font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000077
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!79
!v701!75
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p>&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000078
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!80
!v701!76
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="3"><b>DISCUSSION</b></font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000079
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!81
!v701!77
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">YF vaccines have    been shown to induce long-lasting protection. Notwithstanding, the immunogenicity    of the YF vaccine has been questioned in recent publications.<sup>10,21,25</sup>    It was assessed the performance of the YF vaccines under Good Clinical Practice    guidelines, as part of the clinical validation of a new seed-lot, used to supply    vaccines to the National Immunization Programs in Brazil and other parts of    Latin America and Africa. Brazil is the only producer and the major consumer    of a 17DD substrain YF vaccine, which had never been compared in controlled    studies with the 17D substrain and with placebo. Those elements along with the    blinding and the equivalence type of design expanded the possibilities of analyses    and increased confidence in the results.</font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000080
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!82
!v701!78
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">The results indicated    that the vaccines prepared with WHO-17D substrain and the Brazilian 17DD substrain    induced satisfactory immunological response. High seroconversion rates and GMT    in international units were comparable to those reported in other randomized    trials,<sup>12,15</sup> and in observational studies in adults, in which neutralization    tests were used to assess immunological response and the 17D strain vaccine    was used.<sup>16,20,22,24</sup> Comparability with previous results is limited    by methodological differences, such as laboratory methods for antibody titration,    vaccine dose and method of administration, and age of study subjects. That is    the case of three studies involving the 17DD substrain. Lopes et al<sup>13</sup>    reported 100% seroconversion with a 600 LD<sub>50</sub> /dose vaccine; Guerra    et al<sup>10</sup> observed 76% seropositivity detected through mouse neutralization    tests six months after vaccination with jet injectors; and Stefano et al<sup>21</sup>    obtained 78% seroconversion rate among 9-month-old infants.</font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000081
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!83
!v701!79
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">A substantial proportion    of participants in the present study showed pre-vaccination seropositivity probably    as a result of previous vaccination, which they ignored or concealed. Previous    natural YF infection was less likely as the study site was neither endemic nor    epizootic. As PRNT is considered highly specific, previous infections by other    flaviruses were not expected to cause false-positive results.<sup>17</sup> There    were no striking imbalances in the distribution of pre-vaccination seropositivity    across vaccination and placebo groups that could affect their comparability.    Most of the subjects with pre-vaccination seropositivity showed immunological    response to (re)vaccination, but the differences among comparison groups did    not change substantially when they were included in the analysis.</font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000082
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!84
!v701!80
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Analysis considering    only those seronegative to YF in the pre-vaccination test (per protocol analysis)    showed excellent immunogenicity of the vaccines. The differences between proportions    of seroconversion were never beyond 3%, but for some contrasts, the 90% CI included    values outside the range defining equivalence. This evidence against equivalence    should take into account the practical implications of the arbitrary 5% difference    in seroconversion rates, and 1.5 ratio in GMT, which are conservative. The lowest    confidence limit of -7% in the difference between the new seed-lot and the WHO    seed-lot represented the worst scenario of the complete cohort with substantial    proportion of individuals less likely to show immunological response to vaccination.    For practical purposes, the data provided evidence that there was equivalence    between the two seed-lots of the 17DD vaccine in terms of seroconversion and    magnitude of immune response.</font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000083
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!85
!v701!81
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">The apparent "seroconversion"    in the placebo group may be including genuine fluctuations in the level of previously    existing antibodies and variability of laboratory methods. The effect of unreliability    of measurements is attenuation of effect measures and non-differential misclassification,<sup>7</sup>    which may lead to underestimation of the proportion of seroconversion attributable    to the vaccine compared to placebo. In the present study, a more stringent definition    of seroconversion (fourfold increase in pre-vaccination titters) had little    impact on the observed rates and differences between vaccines.</font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000084
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!86
!v701!82
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">The attributable    proportion of seroconversion among vaccinated, a measurement analogous to efficacy,    estimated the "net effect" (accounting for "seroconversion" in placebo controls)    of vaccination, which was greater in the present study than in another study.<sup>10</sup>    Seropositivity has been generally considered to indicate protection against    natural infection, although direct evidence is lacking in human beings. Serological    correlates of protection against YF are based on data from non-human primates.<sup>8</sup>    Efficacy trials have never been performed so that, in addition to pre-clinical    data, evidence of effectiveness of the YF vaccine relies on indirect evidence    provided by correlation of disease occurrence and vaccination coverage in several    endemic areas over the years.<sup>16</sup></font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000085
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!87
!v701!83
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Gender differences    in vaccine immunogenicity found in other studies <sup>15</sup> were not confirmed    in the present study. Differences in proportion of seroconversion seemed to    favor individuals less than 30 years old, but the magnitude of immune response    did not confirm the advantage. That converges with results obtained by Monath    and colleagues.<sup>15</sup> Generalization of the results to age groups not    included in this study, particularly children below two years of age, are not    warranted considering the potential interference of maternal immunity and concomitant    administration of other vaccines.</font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000086
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!88
!v701!84
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">The levels and    the duration of viremia after YF vaccination are in accordance with previous    findings in the literature.<sup>16</sup> Their implications for safety will    be analysed in another paper.</font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000087
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!89
!v701!85
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">In conclusion,    the vaccine produced from a new seed-lot generated from a single passage of    the 17DD-102/84 seed-lot showed high immunogenicity, and could replace the original    seed-lot for the production of the YF vaccine. The similar performance of the    17D and 17DD vaccines is significant from the perspective of vaccine supply    in YF endemic countries. The 17DD substrain is produced only in Brazil but is    distributed in other Latin American and African countries where 17D vaccines    have been utilized. Moreover, the results indicated a choice of vaccine virus    for the vaccine manufacturer in Brazil. The placebo group allowed a more precise    estimation of the effect of vaccination accounting for concurrent changes unrelated    to vaccination, and shortcomings of serologic methods.</font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000088
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!90
!v701!86
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p>&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000089
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!91
!v701!87
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="3"><b>ACKNOWLEDGEMENTS</b></font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000090
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!92
!v701!88
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">To Dr. Maria de    Lourdes Maia from the Ministry of Health and to General Dr. Dino from the Brazilian    Army, who cleared institutional obstacles that threatened the study; Dr. Est&ecirc;v&atilde;o    Santos from Ag&ecirc;ncia Nacional de Vigil&acirc;ncia Sanit&aacute;ria, who    provided logistical support for staff training; Mrs. Isabella Maluf and Mr.    Ricardo de Carvalho, from Bio-Manguinhos staff, who managed the coding and labeling    of vaccine vials; the Military Commanders and the staff of the Army Units, whose    cooperation was pivotal for the success of field work; the staff of the Health    Care Unit Germano Faria who cooperated in training of interviewers and vaccinators;    and staff from SDE-Escola Nacional de Sa&uacute;de P&uacute;blica, who prepared    forms and other printed material.</font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000091
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!93
!v701!89
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p>&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000092
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!94
!v701!90
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="3"><b>COLLABORATIVE    GROUP FOR THE STUDY OF YELLOW FEVER VACCINES</b></font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000093
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!95
!v701!91
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">In addition to&nbsp;the    paper's authors, members of the Collaborative Group for the Study of Yellow    Fever Vaccines: Dr. Anna Yamamura and Mrs. Luciana Lopes of Bio-Manguinhos;    Mrs. F&aacute;tima Gomes, Mr. Francisco Speranza, Mr. Jaime Ramos, Dr. Marcio    Costa and Dr. Monica Almeidaof Brazilian Army; Mrs. It&aacute;lia Portugal and    Mr. Jorge Silva of Hospital Evandro Chagas.</font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000094
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!96
!v701!92
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p>&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000095
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!97
!v701!93
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="3"><b>DISCLOSURE</b></font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000096
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!98
!v701!94
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Four of the authors    were employed by the vaccine manufacturer (Bio-Manguinhos, Funda&ccedil;&atilde;o    Oswaldo Cruz) and three others worked in other units of Funda&ccedil;&atilde;o    Oswaldo Cruz. Bias from competing interest was prevented by: (1) participation    of members of the Army with expertise in infectious diseases, vaccines and laboratory    virological methods in the Collaborating Group, which conducted the study; and    (2) having two independent university professionals knowledgeable in the field    of infectious diseases and study designs and analysis examine the study protocol,    the setting for laboratory and data processing and analysis.</font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000097
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!99
!v701!95
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p>&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000098
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!100
!v701!96
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica-Normal, sans-serif" size="3"><b>REFERENCES</b></font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000099
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!101
!v701!97
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">1. Armitage P,    Berry G. Statistical methods in medical research. 3<sup>rd</sup> ed. Oxford:    Blackwell Science; 1994.</font></p>    ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v888!1
!v936!^i0034-8910^y2004^o5
!ID 0000100
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!102
!v701!98
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2. Benichou J.    Attributable fraction in exposed. In: Armitage P, Colton T, editors. Encyclopedia    of statistics. Chichester: John Wiley &amp; Sons; 1998. v. 1. p. 49-50.</font></p>    ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v888!2
!v936!^i0034-8910^y2004^o5
!ID 0000101
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!103
!v701!99
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">3. Blackwelder    WC. Equivalence trials. In: Armitage P, Colton T, editors. Encyclopedia of statistics.    Chichester: John Wiley &amp; Sons; 1998. v. 1. p. 1367-72.</font></p>    ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v888!3
!v936!^i0034-8910^y2004^o5
!ID 0000102
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!104
!v701!100
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">4. Bonnel PH. International    regulation of yellow fever vaccination. In: Smithburn KC, DurieuxC, Koerber    R, Penna HA, Dick GWA, Courtois G et al. Yellow fever vaccination. Geneva: World    Health Organization; 1956. Annex 2. p. 205-8. &#91;WHO Monograph Series, 30&#93;</font></p>    ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v888!4
!v936!^i0034-8910^y2004^o5
!ID 0000103
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!105
!v701!101
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">5. De Madrid AT,    Porterfield JS. A simple microculture method for the study of group B arboviruses.    <i>Bull World Health Organ</i> 1969;40:113-21.</font></p>    ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v888!5
!v936!^i0034-8910^y2004^o5
!ID 0000104
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!106
!v701!102
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">6. dos Santos CN,    Post PR, Carvalho R, Ferreira II, Rice CM, Galler R. Complete nucleotide sequence    of yellow fever virus vaccine strains 17DD and 17D-213. <i>Virus Res</i> 1995;35:35-41.</font></p>    ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v888!6
!v936!^i0034-8910^y2004^o5
!ID 0000105
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!107
!v701!103
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">7. Fleiss JL. The    design and analysis of clinical experiments. New York: John Wiley &amp; Sons    Inc.; 1986.</font></p>    ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v888!7
!v936!^i0034-8910^y2004^o5
!ID 0000106
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!108
!v701!104
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">8. Freestone DS.    Yellow fever vaccine. In: Plotkin SA, Mortimer EA, editors. Vaccines. 2<sup>nd</sup>    ed. Philadelphia: W.B. Saunders; 1994. p. 741-79.</font></p>    ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v888!8
!v936!^i0034-8910^y2004^o5
!ID 0000107
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!109
!v701!105
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">9. Galler R, Pugachev    KV, Santos CLS, Ocran SW, Jabor AV, Rodrigues SG et al<i>.</i> Phenotypic and    a molecular analyses of yellow fever 17DD vaccine viruses associated with serious    adverse events in Brazil. <i>Virology</i> 2001;290:309-19.</font></p>    ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v888!9
!v936!^i0034-8910^y2004^o5
!ID 0000108
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!110
!v701!106
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Guerra HL,    Sardinha TM, da Rosa PAT, Costa MFL. Efetividade da vacina antiamar&iacute;lica17D:    uma avalia&ccedil;&atilde;o epidemiol&oacute;gica em servi&ccedil;os e sa&uacute;de.    <i>Rev Panam Salud P&uacute;blica</i> 1997;2:115-20.</font></p>    ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v888!10
!v936!^i0034-8910^y2004^o5
!ID 0000109
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!111
!v701!107
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Hussain AI,    Johnson JA, Freire MS, Heneine W. Identification and characterization of avian    retroviruses in chicken embryo-derived yellow fever vaccines: investigations    of transmission to vaccine recipients. <i>J Virol</i> 2003;77:1105-11.</font></p>    ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v888!11
!v936!^i0034-8910^y2004^o5
!ID 0000110
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!112
!v701!108
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Lang J, Zuckerman    J, Clarke P, Barret P, Kirkpatrick C, Blondeau C. Comparison of the immunogenicity    and safery fo two 17D yellow fever vaccines. <i>Am J Trop Med Hyg</i> 1999;60:1045-50.</font></p>    ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v888!12
!v936!^i0034-8910^y2004^o5
!ID 0000111
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!113
!v701!109
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Lopes OS, Guimaraes    SS, Carvalho R. Studies on yellow fever vaccine. III-Dose response in volunteers.    <i>J Biol Stand</i> 1988;16:77-82.</font></p>    ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v888!13
!v936!^i0034-8910^y2004^o5
!ID 0000112
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!114
!v701!110
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Minist&eacute;rio    da Sa&uacute;de. Funda&ccedil;&atilde;o Nacional de Sa&uacute;de. Programa Nacional    de Imuniza&ccedil;&otilde;es. Manual de procedimentos para vacina&ccedil;&atilde;o.    3<sup>&ordf;</sup> ed. Bras&iacute;lia (DF); 1994.</font></p>    ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v888!14
!v936!^i0034-8910^y2004^o5
!ID 0000113
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!115
!v701!111
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Monath TP,    Nichols R, Archambault WT, Moore L, Marchesani R, Tian J et al. Comparative    safety and immunogenicity of two yellow fever 17D vaccines (Arilvax and IF-Vax)    in a Phase III Multicenter, double-blind clinical trial. <i>Am J Trop Med Hyg</i>    2002;66:533-41.</font></p>    ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v888!15
!v936!^i0034-8910^y2004^o5
!ID 0000114
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!116
!v701!112
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Monath TP.    Yellow fever. In: Plotkin SA, Orenstein WA, editors. Vaccines. 3<sup>rd</sup>    ed. Philadelphia: W.B. Saunders Company; 1999. p. 815-79.</font></p>    ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v888!16
!v936!^i0034-8910^y2004^o5
!ID 0000115
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!117
!v701!113
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Niedrig M,    Lademann M, Emmerich P, Lafrenz M. Assessment of IgG antibodies against yellow    fever virus after vaccination with 17D by different assays: neutralization test,    haemagglutination inhibition test, immunofluorescence assay and ELISA. <i>Trop    Med Int Health</i> 1999;4:867-71.</font></p>    ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v888!17
!v936!^i0034-8910^y2004^o5
!ID 0000116
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!118
!v701!114
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Poland JD,    Calisher CH, Monath TP, Downs WG, Murphy K. Persistence of neutralizing antibody    30-35 years after immunization with 17D yellow fever vaccine. <i>Bull World    Health Organ</i> 1981;59:895-900.</font></p>    ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v888!18
!v936!^i0034-8910^y2004^o5
!ID 0000117
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!119
!v701!115
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Reed GF, Meade    BD, Steinhoff MC. The reverse cumulative distribution plot: a graphic method    of exploratory analysis of antibody data. <i>Pediatrics</i> 1995;96:600-3.</font></p>    ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v888!19
!v936!^i0034-8910^y2004^o5
!ID 0000118
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!120
!v701!116
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Roche JC, Jouan    A, Brisou B, Rodhain R, Fritzell B, Hannoun C. Comparative clinical study of    a new 17D thermostable yellow fever vaccine. <i>Vaccine</i> 1986;4:163-5.</font></p>    ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v888!20
!v936!^i0034-8910^y2004^o5
!ID 0000119
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!121
!v701!117
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Stefano I,    Sato HK, Pannutti CS, Omoto TM, Mann G, Freire MS et al. Recent immunization    against measles does not interfere with the efficacy of yellow fever vaccine.    <i>Vaccine</i> 1999;17:1042-6.</font></p>    ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v888!21
!v936!^i0034-8910^y2004^o5
!ID 0000120
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!122
!v701!118
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">22. Tauraso NM,    Myers MG, Nau EV, O'Brien TC, Spindel SS, Trimmer RW. Effect of interval between    inoculation of live smallpox and yellow-fever vaccines on antigenicity in man.    <i>J Infect Dis</i> 1972;126:362-71.</font></p>    ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v888!22
!v936!^i0034-8910^y2004^o5
!ID 0000121
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!123
!v701!119
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">23. WHO Report    on Global Surveillance of Epidemic-prone Infectious Diseases. 2000. WHO/CDS/CSR/ISR/2000.1.    Available from <a href="http://www.who.int/emc-documents/surveillance/docs/whocdscsrisr2001.%20html/Yellow_fever/Yellow_Fever.htm" target="_blank">http://www.who.int/emc-documents/surveillance/docs/whocdscsrisr2001.    html/Yellow&#151;fever/Yellow&#151;Fever.htm</a>. &#91;2002 Jun 20&#93;.</font></p>    ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v888!23
!v936!^i0034-8910^y2004^o5
!ID 0000122
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!124
!v701!120
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">24. Wolga J, Rodhain    F, Hannoun C, Dodin A, Fritzell B, Loucq C, Stahl JP et al. Evaluation du vaccin    antiamaril thermostable de l'Institut Pasteur chez des voyageurs internationaux.    <i>J Biol Stand</i> 1986;14:289-95.</font></p>    ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v888!24
!v936!^i0034-8910^y2004^o5
!ID 0000123
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!125
!v701!121
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">25. World Health    Organization. Global programme for vaccines and immunization / Division of emerging    and other communicable diseases suveillance and control. Yellow fever &#151; technical    consensus meeting. Geneva; 1998. &#91;Document WHO/EPI/GEN/98.08&#93;.</font></p>    ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v888!25
!v936!^i0034-8910^y2004^o5
!ID 0000124
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!126
!v701!122
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p>&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000125
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!127
!v701!123
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p>&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000126
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!128
!v701!124
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><a name="back10"></a><a href="#top10"><img src="/img/revistas/rsp/v38n5/seta.gif" border="0"></a>    <b>Correspondence to    ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000127
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!129
!v701!125
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<br>   </b></font><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Luiz    Antonio Bastos Camacho    ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000128
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!130
!v701!126
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<br>   Fiocruz    ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000129
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!131
!v701!127
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<br>   Rua Leopoldo Bulh&otilde;es, 1480 sala 820 Manguinhos    ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000130
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!132
!v701!128
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<br>   21041-210 Rio de Janeiro, RJ, Brasil    ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000131
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!133
!v701!129
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<br>   E-mail: <a href="mailto:luiz.camacho@ensp.fiocruz.br">luiz.camacho@ensp.fiocruz.br</a></font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000132
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!134
!v701!130
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Received on 29/1/2004    ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000133
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!135
!v701!131
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<br>   Approved on 8/7/2004    ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000134
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!136
!v701!132
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<br>   </font><font face="Verdana, Arial, Helvetica, sans-serif" size="2">The study    was sponsored by the Funda&ccedil;&atilde;o Oswaldo Cruz, Conselho Nacional    de Desenvolvimento Cient&iacute;fico e Tecnol&oacute;gico (Brazilian Army; Brazilian    National Research Council) (CNPq - Process n. 520673/95-6).    ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000135
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!137
!v701!133
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<br>   </font><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Investigation    conducted at Funda&ccedil;&atilde;o Oswaldo Cruz and Instituto de Biologia do    Ex&eacute;rcito, Rio de Janeiro, RJ, Brasil.    ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000136
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!138
!v701!134
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<br>   </font><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Oral presentation    in the Third World Congress on Vaccines and Immunisation, Opatija Adriatic Riviera,    Croatia, June 4, 2002.</font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000137
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!139
!v701!135
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p>&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000138
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!140
!v701!136
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p>&nbsp;</p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
!ID 0000139
!v002!S0034-8910(04)03800509
!v004!v38n5
!v700!141
!v701!137
!v702!C:\SciELO\Serial\rsp\v38n5\markup\21755.htm
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><a name="back1"></a><a href="#top10">*</a>    The name of the members of the Collaborative Group for the Study of Yellow Fever    Vaccines listed in the end of the article.</font></p>     ^cY
!v705!S
!v706!p
!v708!137
!v709!article
!v880!S0034-89102004000500009
!v882!^v38^n5
!v936!^i0034-8910^y2004^o5
